The results suggested that VPA/HPTA not only can activate macrophage-mediated anti-tumor immunity but also can activate macrophage-CD8+ T cell-mediated anti-tumor immunity to enhance the effects of RT to tumor, thus supported the earlier in vivo results. Here, CD8A is linked to neoplasm.